trial · primary record
Hypofractionated Stereotactic Body Radiotherapy (SBRT)
Head and Neck Squamous Cell Carcinoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 45 |
| Primary completion | 2034-01-31 |
| Primary endpoint | Phase I only: Maximum tolerated dose (MTD) of SBRT in combination with pembrolizumab plus ficerafusp alfa |
| Registry ID | NCT07552558 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:53.886Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07552558
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.